Diane Hollenbaugh is a drug discovery scientist with experience in biologicals research and discovery, and early development.  She joined Good Therapeutics in 2019 and transitioned to Bonum Therapeutics following the acquisition by Roche in 2022.  Prior to Good, she was Executive Director, Immuno-oncology Discovery at AbbVie where she oversaw the growth of IO efforts. Prior to AbbVie, she has experience at multiple large and small companies, including BMS, Medarex, FivePrime Therapeutics and Schering-Plough/Merck. She received her PhD from the California Institute of Technology Division of Chemistry and Chemical Engineering following her BS in Chemistry from the University of Washington.

Using an entirely original strategy to achieve conditional therapeutic regulation, we have developed a novel platform to generate biologics with targeted, conditional activity only when bound to a selected marker. The Antibody Controlled Therapeutics technology is a unique approach that uses the ability of an antibody to bind specifically and competitively to two distinct antigens.  These dual-binding antibodies (DBAs) – a single binding domain able to bind two different antigens – are created where one specificity is a blocker of the therapeutic and the second specificity is the marker. The DBA is incorporated into constructs with the therapeutic fused to the antibody. The result is a protein therapeutic with antibody-like properties and native sequences that is fully “off” in circulation and “on” when bound to the selected marker. Our technology can be applied to the regulation of any functional protein moiety including agonistic and antagonistic antibody binding domains, cytokines, growth factors, and receptors. Our approach constitutes a new class of protein therapeutics with the potential for both increased safety and efficacy applicable to a wide range of biologic targets and disease areas.